Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Introducing ROSALIND


Published on

  • Be the first to comment

  • Be the first to like this

Introducing ROSALIND

  2. 2. 2 ~ $35B personalized cancer gene profiling market by 2018 * * Markets and Markets (2013) 2
  3. 3. 3 Big data problem How to use information from cancer gene profiling to truly personalize therapy 3
  4. 4. 4 Billions 540,000+ 1 size Too many combinations to evaluate? of mutation profiles unique single, double & triple drug combos from just 150 drugs does not fit all! 4
  5. 5. 5 Our solution… Uses gene profile of patient’s tumor to evaluate full range of available therapies Programmable computer simulation of a human cancer cell R O S A L I N DR O S A L I N D
  6. 6. 6 ~100 core processors 10,878* simulations Results in < 2 hours * All possible single drugs and 2 drug combinations for 147 drugs Advantages of ROSALIND  Comprehensiveness and speed
  7. 7. 7 Advantages of ROSALIND  Safety: Simulate rather than experiment  Efficiency: Assign patients to most appropriate therapy or clinical trial when predicted optimal therapies are not yet available
  8. 8. 8 Our vision More personalized cancer treatments Higher remission rates + lower cost of cancer therapy 8
  9. 9. 9 Potential revenue models  Patient-based model  Software as a Service  Online service: web portal
  10. 10. 10 Patient-based model 0.1% market: $1.6 million 1% market: $16.4 million 5% market: $81.9 million 10% market: $163.9 million Assumptions:  Analysis ordered by attending MD  Cost ~$1,000 per patient  ~1.6 million new cases annually in US
  11. 11. 11 Bronze Silver Gold Platinum Annual licensing fee $25,000 $75,000 $150,000 $500,000  Limited users  Limited cases  Medium-sized users  More cases  More users  More features  More cases  Unlimited users  Full features  Unlimited cases Software as a Service model (SaaS)
  12. 12. 12 Online service: web portal  Serves largest population at lowest cost with fastest turn-around and highest security: – Independently, either in the cloud or on secure servers, and/or – A version can be offered through an existing online provider (COTI, Google, etc.) – iTunes type of customizable billing depending on number of drugs/combinations to be evaluated
  13. 13. 13  ROSALIND adopted by medical community; demanded by patients  ROSALIND accepted, reimbursed, and ultimately required, by healthcare insurers and payers Realistic goals
  14. 14. 14 Actual human tumor gene profile  Mutations: • Oncogenes: EGFR, CCND1 • Tumor suppressor: ARID1A Example: Actual Commercial Profile Some common therapies for this profile could include:  Gefitinib  Carboplatin  Paclitaxel (Abraxane)  Gemcitabine  Irinotecan
  15. 15. 15 Actual Patient Profile (cont’d) ROSALIND evaluated just 129 options:  Remission is not possible with any single drug  BUT - remission may be possible with:  Gefitinib or Tarceva or Cetuximab or Panitumumab + Paclitaxel or  Carboplatin + Paclitaxel or  Gemcitabine + Paclitaxel or  Irinotecan + Paclitaxel
  16. 16. 16 Thank you For more information, please contact: Dr. Wayne R. Danter, President & CEO Critical Outcome Technologies, Inc. Suite 213, 700 Collip Circle, London, Ontario, Canada N6G 4X8 T: (519) 858-5157 E:
  17. 17. 17 Disclaimer This presentation may include predictions, estimates or other information that might be considered forward-looking. While these forward looking statements represent COTI’s current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. COTI has based any forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTI’s strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions, and other risks described in documents COTI has filed with the Toronto Stock Exchange and Ontario Securities Commission. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinion only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of any new information or future events.